DK169714B1 - Oily Preparation and Method of Preparation - Google Patents

Oily Preparation and Method of Preparation Download PDF

Info

Publication number
DK169714B1
DK169714B1 DK073293A DK73293A DK169714B1 DK 169714 B1 DK169714 B1 DK 169714B1 DK 073293 A DK073293 A DK 073293A DK 73293 A DK73293 A DK 73293A DK 169714 B1 DK169714 B1 DK 169714B1
Authority
DK
Denmark
Prior art keywords
oil
oily preparation
heated
fine powder
oily
Prior art date
Application number
DK073293A
Other languages
Danish (da)
Other versions
DK73293D0 (en
DK73293A (en
Inventor
Kozo Niwa
Emiyo Niwa
Original Assignee
Emiyo Niwa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emiyo Niwa filed Critical Emiyo Niwa
Publication of DK73293D0 publication Critical patent/DK73293D0/en
Publication of DK73293A publication Critical patent/DK73293A/en
Application granted granted Critical
Publication of DK169714B1 publication Critical patent/DK169714B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/02Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B32LAYERED PRODUCTS
    • B32BLAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B3/00Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
    • B32B3/10Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material
    • B32B3/12Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material characterised by a layer of regularly- arranged cells, e.g. a honeycomb structure
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/50Soya sauce
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10Cereal-derived products
    • A23L7/104Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10Cereal-derived products
    • A23L7/152Cereal germ products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29DPRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D24/00Producing articles with hollow walls
    • B29D24/002Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled
    • B29D24/005Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled the structure having joined ribs, e.g. honeycomb
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11BPRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00Production of fats or fatty oils from raw materials
    • C11B1/06Production of fats or fatty oils from raw materials by pressing
    • C11B1/08Production of fats or fatty oils from raw materials by pressing by hot pressing
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

i DK 169714 B1in DK 169714 B1

OLIEHOLDIG PRÆPARATION OG FREMGANGSMÅDE TIL FREMSTILLING HERAFOIL PREPARATION AND PROCEDURE FOR PREPARING IT

55

BAGGRUND FOR OPFINDELSENBACKGROUND OF THE INVENTION

1. Opfindelsens område 10 Nærværende opfindelse vedrører en olieholdig præparation og en fremgangsmåde til fremstilling heraf, og specielt en olieholdig præparation indeholdende, som effektive komponenter, stoffer, der undertrykker dannelsen af reaktivt oxygen og lipidperoxid i det menneskelige legeme. I det 15 følgende vil disse stoffer blive refereret til som antioxidant stof fer.1. Field of the Invention The present invention relates to an oily preparation and a process for its preparation, and in particular to an oily preparation containing, as effective components, substances which suppress the formation of reactive oxygen and lipid peroxide in the human body. In the following, these substances will be referred to as antioxidant agents.

2. Teknikkens stade 20 For nylig er opmærksomheden blevet henledt på antioxidant-stoffer, som udviser glimrende effekter, når de bliver anvendt til at forebygge og behandle forskellige inflammationer og vanskeligt helbredelige sygdomme såsom kronisk artroreumatisme, tromboflebitis, progressiv systemisk scle- 25 rodermi, Buerger's sygdom, Raynaud's sygdom, vanskeligt behandlelig dermatoulcus og lignende, forårsaget af destruktion af cellulær organisation på grund af reaktivt oxygen og lipidperoxid, dannet i det menneskelige legeme.2. State of the art 20 Recently, attention has been drawn to antioxidant agents which exhibit excellent effects when used to prevent and treat various inflammations and difficult to cure diseases such as chronic arthritis rheumatism, thrombophlebitis, progressive systemic sclerosis, Buerger's disease, Raynaud's disease, difficult-to-treat dermatoulcus, and the like, caused by cellular organization destruction due to reactive oxygen and lipid peroxide, formed in the human body.

30 Det er blevet afklaret ifølge et studium udført af nærværende opfindere, at de ovenanførte antioxidantstoffer omfatter lavmolekylære stoffer såsom flavoner, polypheno-ler, tanniner, tocopheroler, vitamin B^ og lignende indeholdt i en plantevækst, og ved at indtage dem oralt som 35 medicin eller som helsekost bliver dannelsen af ovennævnte reaktive oxygen og lipidperoxid i legemet undertrykket (se DK 169714 B1 2It has been clarified in a study conducted by the present inventors that the above antioxidant substances comprise low molecular weight substances such as flavones, polyphenols, tannins, tocopherols, vitamin B 2 and the like contained in a plant growth, and by taking them orally as 35 medicaments. or as a health food, the formation of the above reactive oxygen and lipid peroxide in the body is suppressed (see DK 169714 B1 2

Journal of Japan Pharmacist Association, nr. 39, bind 12, supplement, "Bio-availability of SOD (Superoxide Dismutase) and crude drug", pp. 1097-1119, publiceret 1. december 1987).Journal of Japan Pharmacist Association, No. 39, Volume 12, Supplement, "Bioavailability of SOD (Superoxide Dismutase) and Crude Drug", pp. 1097-1119, published December 1, 1987).

55

Tidligere har præparationer indeholdende sådanne antioxi-dantstoffer, nemlig et plantefødemiddel ifølge japansk patent no. 1366268 og en antioxidantsammensætning beskrevet i Niwa’s japanske ikke-behandlede offentligt tilgængelige pa-10 tentansøgning nr. 63-79834 været kendt.In the past, preparations containing such antioxidants, namely a plant foodstuff according to Japanese patent no. 1366268 and an antioxidant composition disclosed in Niwa's Japanese Untreated Publicly Available Patent Application No. 63-79834 have been known.

Plantefødemidlet ifølge nr. 1366268 kan opnås ved at blande pulver af grøn the med pulver af bagt upoleret ris og soya-bønnepulver; ved at tilsætte en lille mængde af kojisvamp 15 til blandingen; derefter nedsænke denne pulverblanding i en blanding af sesamolie og soyabønneolie i omkring 4 dage for at ekstrahere effektive komponenter; ved at fjerne bundfald ved centrifugering; og ved at indelukke den tilbageblevne olieholdige substans i en kapsel lavet af gelatine eller 20 lignende.The plant food according to No. 1366268 can be obtained by mixing green tea powder with baked unpolished rice powder and soybean powder; by adding a small amount of koi mushroom 15 to the mixture; then immersing this powder mixture in a mixture of sesame oil and soybean oil for about 4 days to extract effective components; by removing precipitates by centrifugation; and by enclosing the residual oily substance in a capsule made of gelatin or the like.

Antioxidantsammensætningen i no. 63-79834 er opnået ved mild opvarmning af plantefrø eller kim heraf uden at bevirke svidning; ved efterfølgende at brygge disse opvarmede 25 plantematerialer ved tilsætning af en mikroorganisme; og ved hertil at tilsætte en planteolie fra en plante, der også blev mildt opvarmet. Valgfrit bliver vitamin C, vitamin C derivater eller en plantevækst indeholdende disse tilsat til sammensætningen.The antioxidant composition of no. 63-79834 is obtained by gentle heating of plant seeds or germs thereof without causing stinging; by subsequently brewing these heated plant materials by the addition of a microorganism; and by adding a vegetable oil from a plant which was also mildly heated. Optionally, vitamin C, vitamin C derivatives or a plant growth containing these are added to the composition.

3030

Som plantefrø bliver frø anvendt, der indeholder antioxidant s toffer såsom ovenomtalte flavoner, polyphenoler, tanniner, tocopheroler, vitamin B1 og lignende, inklusive ris, hvede, byg, soyabønne, adzukibønne, majs, hatomugi (byg-35 gryn), ærter. Som planteolie anvendes sesamolie, soyabønneolie, olie fra bomuldsfrø, majsolie, farvetidselolie, pri- DK 169714 B1 3 mula- olie, risklidolie, rapsolie, olivenolie og lignende.As plant seeds, seeds containing antioxidant s such as flavones, polyphenols, tannins, tocopherols, vitamin B1 and the like are used, including rice, wheat, barley, soybean, adzuki bean, corn, hatomugi (barley 35 grains), peas. As a vegetable oil, sesame oil, soybean oil, oil from cotton seed, corn oil, color-time oil, pri- DK 169714 B1 3 mula oil, rice bran oil, rapeseed oil, olive oil and the like are used.

Plantefødemidlet ifølge nr. 1366268 er imidlertid fattigt på indhold af antioxidantaktivitet, på grund af dets be-5 handlingsmetode af det rå plantemateriale.However, the plant feed according to No. 1366268 is poor in content of antioxidant activity, due to its treatment method of the raw plant material.

Antioxidantsammensætningen ifølge Niwa nr. 63-79834 fjernede et sådant problem ved bemærkelsesværdigt at øge aktiviteten af antioxidantstoffer ved mild opvarmning af det rå 10 plantemateriale uden at bevirke svidning med lang infrarød bestråling, og modvirkede dermed inaktivering af antioxidantstoffer på grund af høj temperatur, ved at frisætte og omdanne det rå materiale til de lavmolekylære effektive komponenter, og ved at brygge det på denne måde varmebe-15 handlede materiale, for at bevirke yderligere frisætning og omdannelse til de lavmolekylære effektive stoffer.The antioxidant composition of Niwa No. 63-79834 removed such a problem by remarkably increasing the activity of antioxidant substances by gentle heating of the raw plant material without causing long infrared irradiation, thus counteracting inactivation of high temperature antioxidants by releasing and converting the raw material into the low molecular weight effective components, and by brewing the heat-treated material in this way, to effect further release and conversion into the low molecular weight effective substances.

Ifølge studiet udført af nærværende opfindere er det imidlertid blevet tydeliggjort siden da, at omend ovennævnte 20 antioxidantstoffer bemærkelsesværdigt undertrykker dannelsen af det reaktive oxygen og lipidperoxid i reagensglas, så er antioxidantaktiviteten ikke tilstrækkeligt udvist i det menneskelige legeme.However, according to the study by the present inventors, it has been made clear since then that although the above antioxidant substances significantly suppress the formation of the reactive oxygen and lipid peroxide in test tubes, the antioxidant activity is not sufficiently demonstrated in the human body.

25 Det antages, at for at tillade antioxidantstoffer at trænge ind i celler, der lider af en sygdom såsom en inflammatorisk reaktion eller lignende på grund af reaktivt oxygen og lipidperoxidase, er det nødvendigt at passere gennem cellemembranen, der danner overfladen af cellerne. Den menneske-30 lige cellemembran er imidlertid rig på olie og fedtstofkomponenter, og derfor har den en sådan egenskab, at kun olieholdige stoffer tillades passage, således at ovennævnte an-tioxidantsammensætning, der har et lavt indhold af olieholdige stoffer, har en ringe evne til at passere gennem cel-35 lemembranen og trænge ind i cellens indre.It is believed that in order to allow antioxidant substances to enter cells suffering from a disease such as an inflammatory reaction or the like due to reactive oxygen and lipid peroxidase, it is necessary to pass through the cell membrane that forms the surface of the cells. However, the human cell membrane is rich in oil and fat components and, therefore, has such a property that only oily substances are allowed to pass, so that the above antioxidant composition having a low content of oily substances has little ability to to pass through the cell-35 limb membrane and penetrate the interior of the cell.

DK 169714 Bl 4 Nærværende opfindere har derfor gentaget studier for at forbedre antioxidantsammenætningens evne til at penetrere cellemembranen, og samtidigt foretaget yderligere forbedringer i valget af plantearter som råmateriale og i be-5 handlingsmetoden for dette. Som følge heraf er en olieholdig præparation blevet opnået, i hvilken aktiviteten af antioxidant stof ferne som effektive komponenter er høj, og penetrationsevnen ind i det indre af den celle, der lider af en sygdom, er høj, og hermed er nærværende opfindelse fuld-10 endt.Therefore, the present inventors have repeated studies to improve the ability of the antioxidant composition to penetrate the cell membrane, and at the same time made further improvements in the choice of plant species as raw material and in the treatment method thereof. As a result, an oily preparation has been obtained in which the activity of the antioxidant substances as effective components is high and the penetration ability into the interior of the cell suffering from a disease is high, and thus the present invention is complete. ended.

REDEGØRELSE FOR OPFINDELSENDISCLOSURE OF THE INVENTION

Det er et mål for nærværende opfindelse at tilvejebringe en 15 olieholdig præparation og en fremgangsmåde til fremstilling heraf, i hvilken aktiviteten af antioxidantstoffer som effektive komponenter er høj, og hvor penetrationsevnen ind i det indre af cellen i en sygdomslokalisation er høj.It is an object of the present invention to provide an oily preparation and a process for their preparation in which the activity of antioxidant substances as effective components is high and where the penetration of penetration into the interior of the cell in a disease location is high.

20 Fremgangsmåden til fremstilling af den olieholdige præpara tion ifølge nærværende opfindelse omfatter: at opvarme riskim og/eller hvedekim og soyabønne ved en temperatur, der ikke overstiger 100° C; tilsætte koji til det opvarmede materiale; brygge blandingen; derefter pulverisere blandin-25 gen; og tilsætte den opnåede puveriserede blanding til en olieblanding, omfattende en olie opnået fra sesam, der var opvarmet ved en temperatur, der ikke overstiger 100°C, og en olie opnået fra rå sesam, hvori forholdet af olieblandingen til en total mængde af den pulveriserede blanding og 30 olieblandingen er 60 til 95% på vægtbasis.The process for preparing the oily preparation of the present invention comprises: heating rice germ and / or wheat germ and soybean at a temperature not exceeding 100 ° C; adding koji to the heated material; brew mixture; then pulverizing the mixture; and adding the obtained powdered mixture to an oil mixture comprising an oil obtained from sesame heated at a temperature not exceeding 100 ° C and an oil obtained from crude sesame wherein the ratio of the oil mixture to a total amount of the pulverized mixture and the oil mixture is 60 to 95% by weight.

Eftersom råmaterialet righoldigt indeholder antioxidant-stofferne, kan i tilgift til omtalte riskim, hvedekim og soyabønne anvendes plantearter beskrevet i Japanese Un-35 examined Patent Application Laid-open no. 63-79834, det vil sige byg, adzukibønne, majs, hatomugi (byggryn), ærter og DK 169714 B1 5 lignende. Ifølge studiet udført af nærværende opfindere er riskim, hvedekim og soyabønne imidlertid de mest foretrukne råmaterialer.Because the raw material contains rich antioxidant substances, plant species described in Japanese Un-35 examined Patent Application Laid-open no. Can be used in addition to the mentioned rice germ, wheat germ and soybean. 63-79834, that is barley, adzuki bean, corn, hatomugi (barley), peas and DK 169714 B1 5. However, according to the study conducted by the present inventors, rice germ, wheat germ and soybean are the most preferred raw materials.

5 Sideløbende med riskim, hvedekim og soyabønne kan opføres risklid, hatomugi (byggryn), og hvede. Som et råmateriale kan derfor inkluderes mindst et af risklid, hatomugi (byggryn) og hvede sammen med riskim og/eller hvedekim. I alle tilfælde er forholdet mellem kimen (riskim og/eller hvede-10 kim) i kornråmaterialet fortrinsvis mindst mere end eller lig med 1% på vægtbasis.5 Along with rice germ, wheat germ and soybean can be listed rice bran, hatomugi (barley), and wheat. Therefore, as a raw material, at least one of rice bran, hatomugi (barley) and wheat can be included together with rice bran and / or wheat bran. In all cases, the ratio of the germ (rice germ and / or wheat germ) in the cereal raw material is preferably at least more than or equal to 1% by weight.

Antioxidantstofferne i ovenanførte kornråmateriale danner en kompliceret makromolekylær polymer sammen med andre 15 stoffer, og har derfor ingen aktivitet som det er, og det er således nøvendigt at bryde makromolekylebindingerne ved hjælp af mild opvarmning eller lignende og således frisætte lavmolekylære antioxidantstoffer. Hvis opvarmningstemperaturen imidlertid er for høj, bliver de lavmolekylære anti-20 oxidantstoffer inaktiveret, og det er derfor nødvendigt at udvælge en opvarmningsbetingelse, der tager dette faktum i betragtning.The antioxidant substances in the above cereal raw material form a complicated macromolecular polymer with other substances and therefore have no activity as is, thus it is necessary to break the macromolecular bonds by mild heating or the like, thus releasing low molecular weight antioxidants. However, if the heating temperature is too high, the low molecular weight antioxidant substances are inactivated and it is therefore necessary to select a heating condition that takes this fact into account.

For at tilfredsstille en sådan betingelse er det nødvendigt 25 langsomt at opvarme kornråmaterialet ved en temperatur, der ikke overstiger 100°C, og at opvarme i et tilstrækkeligt tidsrum. Mere detaljeret anbringes kornråmaterialet i et kar lavet af keramisk materiale såsom lertøj eller lignende, bestråles med lange infrarøde stråler, fortrinsvis med 30 bølgelænger af 4 til 14 pm, og opvarming foretages, medens der langsomt omrøres, og temperaturen holdes på omkring 90 til 96°C.In order to satisfy such a condition, it is necessary to slowly heat the grain feedstock at a temperature not exceeding 100 ° C and to heat for a sufficient period of time. In more detail, the grain feedstock is placed in a vessel made of ceramic material such as earthenware or the like, irradiated with long infrared rays, preferably with 30 wavelengths of 4 to 14 µm, and heating is done while slowly stirring and the temperature is maintained at about 90 to 96 ° C.

Opvarmningstiden varierer afhængigt af typen af kornsort,The heating time varies depending on the type of grain,

35 således at den ikke kan defineres vilkårligt. Den er imidlertid fortrinsvis omkring 30 minutter til 3 timer. I35 so that it cannot be arbitrarily defined. However, it is preferably about 30 minutes to 3 hours. IN

DK 169714 B1 6 øvrigt er opvarmningsmetoden ikke begrænset til ovenanførte metode, forudsat at antioxidantstofferne i kområmaterialet bliver tilstrækkeligt frisat som lavmolekylære stoffer, medens inaktivering heraf bliver undgået.Furthermore, the heating method is not limited to the above method, provided that the antioxidant substances in the feedstock are sufficiently released as low molecular weight substances, while inactivation thereof is avoided.

55

Efter varmebehandling som beskrevet i det foregående, tilsættes koji (aspergillus orizae) til råmaterialet for at brygge det. Brygningsbetingelserne er fortrinsvis ved 20 til 36°C i omkring 2 til 6 dage. Når brygningen udføres med 10 anvendelse af en gæringstank, er 2 til 3 timer tilstrækkeligt. Denne brygning bliver foretaget for yderligere at fremme frisætteisen og omdannelsen til lavmolekylære stoffer fra antioxidantstofferne i kornråmaterialet, og igennem dette brygningstrin bliver aktiviteten af antioxi-15 dantstofferne bemærkelsesværdigt forøget sammenlignet med råmaterialer, der kun er udsat for varmebehandling.After heat treatment as described above, koji (aspergillus orizae) is added to the feedstock to brew it. The brewing conditions are preferably at 20 to 36 ° C for about 2 to 6 days. When brewing is carried out using a fermentation tank, 2 to 3 hours is sufficient. This brewing is done to further promote the release and conversion to low molecular weight of the antioxidant substances in the grain feedstock, and through this brewing step the activity of the antioxidant substances is significantly increased compared to raw materials subjected only to heat treatment.

Dernæst bliver det bryggede materiale malet til et fint pulver. Formaling kan udføres ved anvendelse af en kommer-20 cielt tilgængelig mølle. Nogle mølletyper genererer imidlertid en høj temperatur under anvendelsen og inaktiverer derfor antioxidantstofferne. Det er derfor fordelagtigt at anvende dem, der ikke generere en høj temperatur under anvendelse. En stenmølle kan for eksempel anvendes.Next, the brewed material is ground to a fine powder. Grinding can be done using a commercially available mill. However, some types of mills generate a high temperature during use and therefore inactivate the antioxidant substances. Therefore, it is advantageous to use those which do not generate a high temperature during use. For example, a stone mill can be used.

2525

Dernæst bliver olien tilberedt ved i et passende forhold at blande en olie indvundet fra opvarmet sesam (i det følgende refereret til som sesampastaolien) med en olie indvundet fra rå sesam, og ovennævnte fine pulver tilsættes til olie-30 blandingen. Sesampastaolien er en olie, der fremkommer ved at male og presse rå sesam, efter at det er opvarmet langsomt i et tilstrækkeligt tidsrum ved en temperatur, der ikke overstiger 100°C. Det fine faste indhold dannet ved formalningen af sesam forbliver imidlertid som det er, 35 således at udseendet får en pastatilstand. Denne sesam-pastaolie indeholder i rigt mål de lavmolekylære antioxi- DK 169714 B1 7 dantstoffer, og ved at anvende den er det muligt at opnå den olieholdige præparation, der har en høj aktivitet af antioxidantforbindelsen.Next, the oil is prepared by mixing in an appropriate ratio an oil recovered from heated sesame (hereinafter referred to as the sesame paste oil) with an oil extracted from raw sesame, and the above fine powder is added to the oil mixture. The sesame paste oil is an oil produced by grinding and pressing raw sesame after it has been heated slowly for a sufficient period of time at a temperature not exceeding 100 ° C. However, the fine solid content formed by the grinding of sesame remains as is, so that the appearance is given a paste state. This sesame paste oil richly contains the low molecular weight antioxidants and by using it it is possible to obtain the oily preparation having a high activity of the antioxidant compound.

5 Denne sesampastaolie har imidlertid en høj viscositet, og størrelsen af en oliemikrodråbe er også stor, således at den præparation, i hvilken kun sesampastaolien bliver tilsat til ovennævnte fine pulver, har en ringe penetrerende evne ind i det indre af celler i et sygdomsområde. Når se- 10 samolie indvundet fra rå sesam imidlertid tilsættes til sesampastaolien, kan størrelsen af mikrodråben være lille, og den penetrerende evne ind i det indre af celler i et sygdomsområde er forbedret.However, this sesame paste oil has a high viscosity, and the size of an oil microdroplet is also large, so that the preparation in which only the sesame paste oil is added to the above fine powder has little penetrating ability into the interior of cells in a disease region. However, when seed oil recovered from raw sesame is added to the sesame paste oil, the size of the microdroplet may be small and the penetrating ability into the interior of cells in a disease area is enhanced.

15 Den olie, der opsamles fra rå sesam, er en olie, der er indvundet ved at male det rå sesam, som det er, og presse det og fjerne fast indhold, og den er kommercielt tilgænglig som en almindelig sesamolie. Eftersom blandingsforholdet mellem sesampastaolien og den almindelige sesamolie er 20 forskellig og også afhængende af mængden af det fine pulver, der skal tilsættes, kan forholdet ikke ukritisk defineres. Det er fortrinsvis 1 til 3 vægtdele af den alminde-lie sesamolie i forhold til 1 vægtdel af sesampastaolien.The crude sesame oil is an oil extracted by grinding the raw sesame as it is, squeezing it and removing solid contents, and it is commercially available as a regular sesame oil. Since the mixing ratio of the sesame paste oil to the regular sesame oil is different and also depending on the amount of fine powder to be added, the ratio cannot be uncritically defined. It is preferably 1 to 3 parts by weight of the general sesame oil relative to 1 part by weight of the sesame paste oil.

25 Forholdet mellem olieblandingen og det fine pulver, der tilsættes hertil, er et sådant, at den blandede olie bliver 60 til 95 % på vægtbasis i forhold til en total mængde af begge. Hvis olieblandingen er mindre end 60% på vægtbasis, bliver evnen til at passere gennem cellemembranen ringe. På 30 den anden side, hvis oliblandingen overstiger 95% på vægtbasis, bliver koncentrationen af antioxidantstoffer som de effektive komponenter lille, således at effekten med hensyn til undertrykkelse af det reaktive oxygen og lipidperoxid også formindskes.The ratio of the oil mixture to the fine powder added thereto is such that the mixed oil becomes 60 to 95% by weight relative to a total amount of both. If the oil mixture is less than 60% by weight, the ability to pass through the cell membrane becomes poor. On the other hand, if the oily mixture exceeds 95% by weight, the concentration of antioxidant substances as the effective components becomes small, so that the effect of suppression of the reactive oxygen and lipid peroxide is also diminished.

Den olieholdige præparation ifølge nærværende opfindelse, 35 DK 169714 B1 8 som indtages oralt, kan fremstilles ved at tilsætte det fine pulver til olieblandingen og indeslutte det i en gelatinekapsel eller lignende, så snart olieblandingen er tilberedt. Materialeblandingen kan imidlertid modnes fortrins-5 vis ved 20 til 35°C i omkring 3 til 30 dage, eller mere fordelagtigt ved 28 til 30°C i omkring 1 uge før indkapsling.The oily preparation according to the present invention, orally consumed, can be prepared by adding the fine powder to the oil mixture and enclosing it in a gelatin capsule or the like as soon as the oil mixture is prepared. However, the material mixture can preferably mature at 20 to 35 ° C for about 3 to 30 days, or more advantageously at 28 to 30 ° C for about 1 week before encapsulation.

Ved at anvende modningsbehandlingen bliver frisætteisen og 10 omdannelsen af antioxidantstoffer til lavmolekylære stof fer yderligere fremmet på grund af det koji, som resterer i det fine pulver, og antioxidantstofferne optages godt i olieblandingen, således at aktiviteten og den osmotiske evne af de reaktive stoffer ind i det indre af cellen yder-15 ligere er forbedrede.By applying the ripening treatment, the release ice and the conversion of antioxidant substances to low molecular weight are further promoted due to the koji remaining in the fine powder and the antioxidant substances are well absorbed in the oil mixture so that the activity and the osmotic ability of the reactants into the the interior of the cell is further enhanced.

Den olieholdige præparation ifølge nærværende opfindelse kan også inkludere et råmateriale af korn omfattende riskim eller hvedekim og soyabønne og valgfrit mindst en af risk-20 lid, hatomugi (byggryn) eller hvede, som laves til et fint pulver som det er, uden opvarmning og brygning, og tilsættes til olieblandingen sammen med det ovenanførte opvarmede og bryggede fine pulver.The oily preparation of the present invention may also include a raw material of cereals comprising rice germ or wheat germ and soybean and optionally at least one of the risk 20 lid, hatomugi (barley) or wheat which is made into a fine powder as is, without heating and brewing. , and added to the oil mixture together with the above heated and brewed fine powder.

25 I det fine pulver af kornråmaterialet, som ikke er opvarmet og brygget, er antioxidantstofferne som den effektive komponent ikke frisat og omdannet til lavmolekylære stoffer. Når det imidlertid tilsættes til olieblandingen sammen med det opvarmede og bryggede fine pulver, foregår frisætningen 30 og omdannelsen af antioxidantstoffer til lavmolekylære stoffer gradvis selv efter indkapsling, på grund af det koji som forbliver i det bryggede fine pulver, således at der er en sådan fordel, at effekten med hensyn til undertrykkelse af dannelsen af det reaktive oxygen og lipid-35 peroxid bliver vedligeholdt i en lang periode.25 In the fine powder of the grain raw material which is not heated and brewed, the antioxidant substances as the effective component are not released and converted into low molecular weight substances. However, when added to the oil mixture with the heated and brewed fine powder, the release 30 and the conversion of antioxidant substances to low molecular weight occur gradually even after encapsulation, due to the koji remaining in the brewed fine powder, so that there is such an advantage , that the effect of suppressing the formation of the reactive oxygen and lipid peroxide is maintained for a long period.

DK 169714 B1 9 På den anden side, i den oliepræparation, i hvilken kun det opvarmede og bryggede fine pulver bliver anvendt, på grund af enzymreaktioner og lignende, som kontinuerligt fortsætter selv efter indkapsling, bliver antioxidantstofferne som 5 de effektive komponenter, gradvis nedbrudt, således at den effektive periode er kort sammenlignet med en præparation, i hvilken det ubehandlede fine pulver tilsættes.DK 169714 B1 On the other hand, in the oil preparation in which only the heated and brewed fine powder is used, due to enzyme reactions and the like, which continue continuously even after encapsulation, the antioxidant substances as the effective components are gradually degraded, so that the effective period is short compared to a preparation in which the untreated fine powder is added.

I det tilfælde, hvor den tilsatte mængde af ubehandlet fint 10 pulver imidlertid er for stor, falder aktiviteten af den effektive komponent. Derfor er det fordelagtigt, at det u-behandlede fine pulver er omkring 0.5 til 1 vægtdel baseret på 1 vægtdel af det opvarmede og bryggede fine pulver. I øvrigt er olieblandingen også i dette tilfælde, hvor 2 15 typer af fint pulver inkluderes, 60 til 95% på vægtbasis i forhold til den totale mængde.However, in the case where the amount of untreated fine 10 powder added is too large, the activity of the effective component decreases. Therefore, it is advantageous that the untreated fine powder is about 0.5 to 1 part by weight based on 1 part by weight of the heated and brewed fine powder. Incidentally, in this case too, where 2 15 types of fine powder are included, the oil mixture is 60 to 95% by weight relative to the total amount.

I den på denne måde frembragte olieholdige præparation ifølge nærværende opfindelse er både aktiviteten af anti-20 oxidantstofferne og den osmotiske kraft ind i det indre af cellen høj, og som også klarlagt fra resultater af kliniske undersøgelser som beskrevet i det følgende, udviser den bemærkelsesværdige effekter mod forskellige inflammationer og vanskeligt helbredelige sygdomme, for hvilke den terapeu-25 tiske effekt har været utilstrækkelig med konventionelle antiinflammatoriske midler.In the thus obtained oily preparation of the present invention, both the activity of the antioxidant and the osmotic force into the interior of the cell is high, and as also clarified from results of clinical studies as described below, it exhibits remarkable effects. against various inflammations and difficult to cure diseases for which the therapeutic effect has been insufficient with conventional anti-inflammatory agents.

Den olieholdige præparation ifølge nærværende opfindelse kan indkapsles med gelatine eller lignende og indtages 30 oralt som medicin. I tilgift hertil, i tilfælde af abnormal pigmentation såsom dermatitis, chloroasma, fregner og lignende, eller rynker og lignende, kan den olieholdige præparation direkte påføres på et angrebet område. Foruden til dermatitis og lignende kan nærværende olieholdige præpara-35 tion også anvendes til fremskredne sygdomme og svært helbredelige sygdomme såsom kronisk artroreumatisme, trombo- DK 169714 B1 10 flebitis, progressiv systemisk sclerodermi, Buerger's sygdom, Raynaud's sygdom, vanskeligt behandelig dermatoulcus og lignende. Præparationen ifølge opfindelsen har også effekter på behandling og forebyggelse af andre forskellige 5 forureningsbetingede sygdomme, forbrændinger, ydre sår, træthed, tømmermænd, forstoppelse og lignende.The oily preparation of the present invention can be encapsulated with gelatin or the like and taken orally as a medicine. In addition, in the case of abnormal pigmentation such as dermatitis, chloroasma, freckles and the like, or wrinkles and the like, the oily preparation may be applied directly to an affected area. In addition to dermatitis and the like, this oily preparation can also be used for advanced and curable diseases such as chronic arthritis, thromboembolism, phlebitis, progressive systemic scleroderma, Buerger's disease, Raynaud's disease, difficult-to-treat dermatoulcus and the like. The preparation according to the invention also has effects on the treatment and prevention of other various pollution-related diseases, burns, external wounds, fatigue, hangovers, constipation and the like.

I tilgift har den olieholdige præparation ifølge nærværende opfindelse ingen sideeffekter på grund af anvendelsen af 10 kun korn, koji og sesam som råmaterialer, således at den er mulig at indtage oralt som en helsekost for at vedligeholde og forbedre helbredet. Det er unødvendigt at bemærke, at når en præparation fremstilles, er det valgfrit at tilføje ekstra medicin eller ingredienser, der er brugbare for hel-15 bredet, såsom forskellige vitaminer, mineraler og lignende, og aromastoffer, smagsstoffer, farvestoffer og lignende.In addition, the oily preparation of the present invention has no side effects due to the use of only cereals, koji and sesame as raw materials, so that it is possible to ingest orally as a health food to maintain and improve health. Needless to say, when preparing a preparation, it is optional to add additional medications or ingredients useful for the whole variety, such as various vitamins, minerals and the like, and flavors, flavors, dyes and the like.

Eksempel på fremstilling 20 Hver del af riskim, soyabønne, risklid, hatomugi (byggryn) og hvede blev overført til et kar lavet af keramisk materiale bestrålet med lange infrarøde stråler med en bølgelængde af 4 til 14 pm, og opvarmet til 90 til 96eC i 3 timer under langsom omrøring for ikke at bevirke svidning.Example 20 Preparation Each portion of rice germ, soybean, rice bran, hatomugi (barley) and wheat was transferred to a vessel made of ceramic material irradiated with long infrared rays with a wavelength of 4 to 14 µm, and heated to 90 to 96 ° C for 3 hours. hours of slow stirring so as not to cause stinging.

25 Dernæst blev koji tilsat som 3% af en total mængde for at brygge ved 36 til 40°C i 72 timer, og så blev det bryggede materiale malet til et fint pulver med anvendelse af en stenmølle. Yderligere blev ovennævnte fem kornråmaterialer, som ikke blev opvarmet og brygget, malet med en stenmølle 30 for at få et fint pulver i samme mængde. På den anden side blev sesam opvarmet på samme måde som ovenanførte kornmaterialer, og efter at det var malet med en stenmølle, blev det presset for at få en sesampastaolie.Next, koji were added as 3% of a total amount to brew at 36 to 40 ° C for 72 hours, and then the brewed material was ground to a fine powder using a stone mill. Further, the above-mentioned five grain raw materials, which were not heated and brewed, were painted with a stone mill 30 to obtain a fine powder in the same amount. On the other hand, sesame was heated in the same way as above grain materials, and after it was painted with a stone mill, it was pressed to get a sesame paste oil.

35 Dernæst blev 28.1 dele på vægtbasis af sesampastaolien blandet med 48.9 dele på vægtbasis af en kommercielt til- DK 169714 B1 11 gængelig sesamolie; til denne blanding blev tilsat 11.5 dele på vægtbasis af det ubehandlede fine pulver; og den opnåede blanding blev omrørt homogent. Den opnåede blanding blev modnet ved 28°C i 1 uge og derefter indkapslet i ge-5 latine for at få en olieholdig præparation.Next, 28.1 parts by weight of the sesame paste oil were mixed with 48.9 parts by weight of a commercially available sesame oil; to this mixture were added 11.5 parts by weight of the untreated fine powder; and the resulting mixture was stirred homogeneously. The resulting mixture was matured at 28 ° C for 1 week and then encapsulated in gelatin to obtain an oily preparation.

Effekt af opfindelsen [I] In vitro afprøvning 10 (1) Som en in vitro afprøvning af evnen til at trænge ind til og penetrere olieholdige steder blev den olieholdige præparation ifølge fremstillingseksemplet tilsat til et TBA (thiobarbitursyre) reaktionssystem, i hvilket en olieagtig umættet fedtsyre (decosahexaensyre) blev reageret med 15 reaktivt oxygen, frembragt ved ultraviolette stråler, og dannede lipidperoxid, og graden af undertrykkelse af dannelse af lipidperoxid blev målt.Effect of the Invention [I] In Vitro Test 10 (1) As an in vitro test of the ability to penetrate and penetrate oily sites, the oily preparation of the Example Example was added to a TBA (thiobarbituric acid) reaction system in which an oily unsaturated fatty acid (decosahexaenoic acid) was reacted with 15 reactive oxygen, produced by ultraviolet rays, and formed lipid peroxide, and the degree of suppression of lipid peroxide formation was measured.

Til 0.1 cc af decosahexaensyre fortyndet 100 gange blev 20 tilsat 1.8 mg/ml af prøven af den olieholdige præparation ifølge opfindelsen, og det dannede lipidperoxid blev målt med TBA reaktionen. I TBA reaktionen blev blandet 0.2 ml af 7% natriumdodecylsulfat, 2 ml af 0.1 N HC1, og 0.3 ml af phosphorwolframsyre; 1.8 mg/ml af prøven blev tilsat til 25 blandingen; 1 ml af et reagens blev tilsat i hvilket 0.67% TBA var blandet med eddikesyre i forholdet 1:1; og målingen blev udført med anslag ved 515 nm og emission ved 553 nm ved anvendelse af et fluorescensspektrofotometer.To 0.1 cc of decosahexaenoic acid diluted 100-fold was added 1.8 mg / ml of the sample of the oily preparation of the invention and the lipid peroxide formed was measured with the TBA reaction. In the TBA reaction, 0.2 ml of 7% sodium dodecyl sulfate, 2 ml of 0.1 N HCl, and 0.3 ml of phosphorus tungstic acid were mixed; 1.8 mg / ml of the sample was added to the mixture; 1 ml of a reagent was added in which 0.67% TBA was mixed with acetic acid in a 1: 1 ratio; and the measurement was performed with estimates at 515 nm and emission at 553 nm using a fluorescence spectrophotometer.

30 Som sammenlignende eksempler blev anvendt plantenæringsmid-let ifølge japansk patent no. 1366268 (sammenlignende eksempel 1) og antioxidantsammensætningen beskrevet i j apansk ikke-behandlet offentligt tilgængelig patentansøgning nr. 63-79834 (sammenlignende eksempel 2), og målinger blev ud-35 ført på samme måde. Resultater er vist i tabel 1.As comparative examples, the plant nutrient was used according to Japanese patent no. 1366268 (Comparative Example 1) and the antioxidant composition disclosed in Japanese Unpublished Public Application Patent Application No. 63-79834 (Comparative Example 2), and measurements were made in the same manner. Results are shown in Table 1.

12 DK 169714 B112 DK 169714 B1

Tabel 1 5 Prøve Gennemsnit (6 minutters værdi)Table 1 5 Sample Average (6 minute value)

Kontrol 461 ± 62 10 (UV+) ·£· jfe tfeControl 461 ± 62 10 (UV +) · £ · jfe tfe

Olieholdig præparation ifølge 121 ± 13 nærværende opfindelse (1.8 mg/ml)Oily preparation according to 121 ± 13 of the present invention (1.8 mg / ml)

icHIch

15 Sammenlignende eksempel 1 271 ± 34 (1.8 mg/ml) *Comparative Example 1 271 ± 34 (1.8 mg / ml) *

Sammenlignende eksempel 2 358 ± 45 (1.8 mg/ml) 20 UV+: ultraviolet bestråling «il· : 0.01 < P < 0.05 (i forhold til kontrol) : P < 0.01 (i forhold til kontrol) 25 : P < 0.0001 (i forhold til kontrol)Comparative Example 2 358 ± 45 (1.8 mg / ml) 20 UV +: ultraviolet irradiation λ · 0.01 <P <0.05 (relative to control): P <0.01 (relative to control) 25: P <0.0001 (relative to to control)

Afprøvningsresultater 30Test results 30

Selvom enhver af prøverne signifikant undertrykkede dannelsen af lipidperoxid (TBA reaktive stoffer) fra den umættede fedtsyre (decosahexaensyre) med bestråling af ultraviolette stråler (^2), undertrykte specielt den olieholdige præ-35 paration ifølge nærværende opfindelse bemærkelsesværdigt denne dannelse (P < 0.0001). Dette resultat understøtter DK 169714 B1 13 det faktum, at den olieholdige præparation ifølge nærværende opfindelse har en højere aktivitet af antioxidantstof-fet, og en større penetrationsevne ind i det indre af cellen, i hvilken en sygdom forekommer, sammenlignet med kon-5 ventionelle præparationer (Sammenlignende eksempel 1 og 2).Although each of the samples significantly suppressed the formation of lipid peroxide (TBA reactants) from the unsaturated fatty acid (decosahexaenoic acid) with irradiation of ultraviolet rays (2), the oily preparation of the present invention particularly repressed this formation (P <0.0001). . This result supports the fact that the oily preparation of the present invention has a higher activity of the antioxidant fat, and a greater penetration ability into the interior of the cell in which a disease occurs, as compared to conventional preparations. (Comparative Examples 1 and 2).

(2) Et [3,4- H^j-antioxidantstof blev fremstillet, i hvilket det lavmolekylære antioxidantstof indeholdt i den olieholdige præparation ifølge nærværende opfindelse blev 3 10 mærket med en isotop ( H); det blev indført i et humant væv 3 i et reagensglas; og tælletallene (cpm) af [ H] bundet til dets cellemembran blev målt med en scintillationstæller; derved blev evnen til at trænge ind til cellemembranen afprøvet (mærket tritieret thymidin var 2 C^/mM).(2) An [3,4-H₂J antioxidant substance was prepared in which the low molecular weight antioxidant substance contained in the oily preparation of the present invention was labeled with an isotope (H); it was introduced into a human tissue 3 in a test tube; and the count numbers (cpm) of [H] bound to its cell membrane were measured with a scintillation counter; thereby, the ability to penetrate the cell membrane was tested (labeled tritiated thymidine was 2 C / mM).

1515

De samme undersøgelser blev også udført for Sammenlignende eksempel 1 og 2. Resultater er vist i tabel 2. Som vist i tabel 2, havde den olieholdige præparation ifølge nærværende opfindelse den højeste affinitet til cellemembraner i 20 forhold til Sammenlignende eksempel 1 og 2.The same studies were also performed for Comparative Examples 1 and 2. Results are shown in Table 2. As shown in Table 2, the oily preparation of the present invention had the highest affinity for cell membranes in 20 relative to Comparative Examples 1 and 2.

Tabel 2 5 14 DK 169714 B1Table 2 5 14 DK 169714 B1

Prøve cpm indbyggetSample cpm built-in

Kontrol 15643 cpm / 10^ celler 3 10 Olieholdig præparation ifølge 56372 cpm / 10 celler nærværende opfindelse (1.8 mg/ml) 3Control 15643 cpm / 10 6 cells 3 Oily preparation according to 56372 cpm / 10 cells of the present invention (1.8 mg / ml) 3

Sammenlignende eksempel 1 33451 cpm / 10 celler (1.8 mg/ml) 15 3Comparative Example 1 33451 cpm / 10 cells (1.8 mg / ml) 3

Sammenlignende eksempel 2 30567 cpm / 10 celler (1.8 mg/ml) 20 (3) Den olieholdige præparation ifølge nærværende opfindelse blev udsat for ultralydsbehandling og tilsat til et system, der dannede reaktivt oxygen (neutrophiler og xan-thin-xanthinoxidase), således at en omdannet koncentration 25 i det levende væv blev 1.6 mg/ml; og tre typer af reaktivt oxygen f ^2^2 ) blev målt for at sammenligne med tilfældet uden tilsætning (kontrol). Den omdannede koncentration i levende væv er en mængde, der antages at forefindes i blod, når en almindelig indtagelsesmængde pr. dag (9 30 gi tilfældet af den olieholdige præparation ifølge nærværende opfindelse) bliver absorberet ind i et levende legeme.Comparative Example 2 30567 cpm / 10 cells (1.8 mg / ml) 20 (3) The oily preparation of the present invention was subjected to ultrasonic treatment and added to a reactive oxygen (neutrophil and xanthine xanthine oxidase) system so that a converted concentration in the living tissue was 1.6 mg / ml; and three types of reactive oxygen f ^ 2 ^ 2) were measured to compare with the case without addition (control). The converted concentration in living tissue is an amount believed to be present in blood when a normal intake amount per day (930 g in the case of the oily preparation of the present invention) is absorbed into a living body.

Målemetoderne for de tre typer af reaktivt oxygen er som 35 følger.The measurement methods for the three types of reactive oxygen are as follows.

DK 169714 B1 15DK 169714 B1 15

For 02~ blev metoden anvendt, i hvilken mængden af reduktion af ferricytochrom C på grund af O2 blev målt ved en bølgelængde af 550 nm med et spektrofotometer fra Beckman, og konverteret til mængden af O2-.For O 2 ~, the method was used in which the amount of ferric cytochrome C reduction due to O 2 was measured at a wavelength of 550 nm with a Beckman spectrophotometer and converted to the amount of O 2 -.

55

For Η2θ2,. afhængigt af det faktum at H202 nedsætter fluorescensen dannet af scopoletin ved tilstedeværelse af peroxidase, ved at anvende scopoletin og peroxidase blev graden af formindskelse af fluorescens målt ved anvendelse af 10 et fluorescensspektrofotometer fra Hitachi Ltd. med anslag ved 370 nm og emission ved 460 nm.For Η2θ2 ,. Depending on the fact that H 2 O 2 decreases the fluorescence produced by scopoletin in the presence of peroxidase, using scopoletin and peroxidase, the degree of fluorescence reduction was measured using a Hitachi Ltd. fluorescence spectrophotometer. with impact at 370 nm and emission at 460 nm.

For OH* under anvendelse af princippet at alfa-ketomethiol-butansyre (KMB) reagerer med OH* under dannelse af ethylen-15 gas, blev metoden anvendt, i hvilken ethylengas blev kvan-titeret med en gaschromatograf fra Hitachi Ltd., for på denne måde at konvertere det dannede ethylengas til OH*. De samme undersøgelser blev også udført for Sammenlignende eksempel 1 og 2. Resultater er vist i tabel 3.For OH * using the principle that alpha-ketomethiol-butanoic acid (KMB) reacts with OH * to form ethylene gas, the method was used in which ethylene gas was quantitated by a gas chromatograph from Hitachi Ltd., for which method of converting the formed ethylene gas to OH *. The same studies were also performed for Comparative Examples 1 and 2. Results are shown in Table 3.

2020

Tabel 3 16 DK 169714 B1Table 3 16 DK 169714 B1

Reaktivt oxygen 5Reactive Oxygen 5

Prøve 02" H202 OH'Sample 02 "H202 OH '

Kontrol 1.532 nmol 485 pmol 854 pmol 10 Olieholdig præparation 0.589 nmol 161 pmol 283 pmol ifølge nærværende opfindelse (1.8 mg/ml)Control 1,532 nmol 485 pmol 854 pmol 10 Oily Preparation 0.589 nmol 161 pmol 283 pmol according to the present invention (1.8 mg / ml)

Sammenlignende eksempel 1 1.285 nmol 403 pmol 707 pmol 15 (1.8 mg/ml)Comparative Example 1 1.285 nmol 403 pmol 707 pmol 15 (1.8 mg / ml)

Sammenlignende eksempel 2 0.231 nmol 538 pmol 108 pmol (1.8 mg/ml) 20Comparative Example 2 0.231 nmol 538 pmol 108 pmol (1.8 mg / ml) 20

Antioxidanteffekten af den olieholdige præparation ifølge nærværende opfindelse var lidt mindre end den i Sammenlig-25 nende eksempel 2, imidlertid var den viste antioxidantef-fekt større end i Sammenlignende eksempel 1. Imidlertid, som vist i ovennævnte tabeller 1 og 2, har Sammenlignende eksempel 2 et lavere indhold af olieagtige stoffer, således at det har ringe evne til at trænge ind til cellen, i hvil-30 ken en sygdom forekommer.The antioxidant effect of the oily preparation of the present invention was slightly less than that of Comparative Example 2, however, the antioxidant effect shown was greater than that of Comparative Example 1. However, as shown in Tables 1 and 2 above, Comparative Example 2 a lower content of oily substances so that it has little ability to penetrate the cell in which a disease occurs.

Derfor, når det vurderes som en helhed, er den olieholdige præparation ifølge nærværende opfindelse, i hvilken anti-oxidanteffekten er høj, og penetrationsevnen ind i det 35 indre af cellen i et sygdomsområde er højest, mest fremragende som et antioxidantmiddel.Therefore, when considered as a whole, the oily preparation of the present invention in which the antioxidant effect is high and the penetration ability into the interior of the cell in a disease area is highest is most excellent as an antioxidant agent.

DK 169714 B1 17 II Kliniske undersøgelserDK 169714 B1 17 II Clinical studies

Den terapeutiske effekt blev undersøgt på 96 patienter med 5 autoimmunsygdomme, kollagensygdomme såsom kronisk arthro- reumatisme, hæmastenose, nephritis, hapatocirrhose, chloasma, fregner og lignende, som hidtil har været resistent overfor eller er blevet forværret efter behandling med et hvilket som helst af ikke-steroide antiflogistiske lægemid-10 ler, steroider og antioxidantsammensætningen i Sammenlignende eksempel 2. Resultaterne er vist i tabel 4.The therapeutic efficacy was investigated in 96 patients with 5 autoimmune diseases, collagen diseases such as chronic arthro-rheumatism, hemastenosis, nephritis, hapatocirrhosis, chloasma, freckles and the like, which have hitherto been resistant to or worsened after treatment with any of the -steroidal antiphlogistic drugs, steroids and the antioxidant composition of Comparative Example 2. The results are shown in Table 4.

18 DK 169714 Bl18 DK 169714 Pg

Tabel 4 Prøve 5 Olieholdig Sammenlignende Sammenlignende præparation eksempel 1 eksempel 2 ifølge nær- (1.8 mg/ml) (1.8 mg/ml) værende opfindelse 10 (1.8 mg/ml)Table 4 Sample 5 Oily Comparative Comparative Preparation Example 1 Example 2 of Near- (1.8 mg / ml) (1.8 mg / ml) Present Invention 10 (1.8 mg / ml)

SygdomDisease

Kronisk 13/18 (72%) 0/7 (0%) 4/14 (28%) arthroreu-15 matismeChronic 13/18 (72%) 0/7 (0%) 4/14 (28%) arthroreum matism

Angitis 3/5 (60%) 0/3 (0%) 1/4 (25%)Angitis 3/5 (60%) 0/3 (0%) 1/4 (25%)

Progressiv 9/12 (75%) 2/10 (20%) 6/12 (50%) 20 systemisk sklero-dermiProgressive 9/12 (75%) 2/10 (20%) 6/12 (50%) 20 Systemic scleroderma

Dermato- 6/8 (75%) 2/12 (16%) 6/13 (46%) 25 myocitisDermato- 6/8 (75%) 2/12 (16%) 6/13 (46%) 25 Myocitis

Trombo- 2/3 (66%) 0/4 (0%) 1/5 (20%) flebitis 30 Buerger's 6/8 (75%) 0/3 (0%) 3/6 (50%) sygdomThrombosis 2/3 (66%) 0/4 (0%) 1/5 (20%) phlebitis 30 Buerger's 6/8 (75%) 0/3 (0%) 3/6 (50%) disease

Raynaud's 10/12 (83%) 3/8 (37%) 7/12 (58%) sygdom 35 varices 8/11 (72%) 4/9 (44%) 11/15 (73%) crurisRaynaud's 10/12 (83%) 3/8 (37%) 7/12 (58%) disease 35 varices 8/11 (72%) 4/9 (44%) 11/15 (73%) cruris

Vanskeligt 3/5 (60%) 1/5 (20%) 2/6 (33%) 40 helbredelig dermatoulcusDifficult 3/5 (60%) 1/5 (20%) 2/6 (33%) 40 curable dermatoulcus

Chloasma 11/14 (78%) 4/12 (33%) 17/25 (68%) fregner 45 50Chloasma 11/14 (78%) 4/12 (33%) 17/25 (68%) freckles 45 50

Claims (7)

1. Olieholdig præparation, kendetegnet ved, at være opnået ved at opvarme riskim og/eller hvedekim og soy abønne ved en temperatur ikke overstigende 100®C, ved at lave det opvarmede materiale til et fint pulver, ved at tilsætte koji til det pulveriserede materiale og brygge det 10 pulveriserede materiale, og ved at tilsætte det på denne måde bryggede materiale til en olieblanding indeholdende en pastaolie indvundet fra sesam opvarmet ved en temperatur ikke overstigende 100°C, og en olie indvundet fra rå sesam, hvori et forhold af omtalte olieblanding til en total mæng-15 de af det fine pulver og olieblandingen er 60 til 95% på vægtbasis.An oily preparation, characterized by being obtained by heating rice germ and / or wheat germ and soybean at a temperature not exceeding 100 ° C, by making the heated material into a fine powder, by adding koji to the powdered material and brewing the powdered material, and by adding the material thus brewed to an oil mixture containing a pasta oil recovered from sesame heated at a temperature not exceeding 100 ° C, and an oil recovered from raw sesame, wherein a ratio of said oil mixture is obtained to a total amount of the fine powder and the oil mixture is 60 to 95% by weight. 2. Olieholdig præparation ifølge krav 1, kende tegnet ved, at den yderligere omfatter et kornrå- 20 materiale indeholdende riskim og/eller hvedekim og soya-bønne lavet til et fint pulver uden opvarmning og brygning.An oily preparation according to claim 1, characterized in that it further comprises a grain raw material containing rice germ and / or wheat germ and soybean made into a fine powder without heating and brewing. 3. Olieholdig præparation ifølge krav 1 eller 2, kendetegnet ved, at nævnte opvarmede eller 25 ikke-opvarmede kornråmateriale omfatter, foruden riskim og/eller hvedekim og soyabønne, mindst en af risklid, hato-mugi (byggryn) eller hvede.An oily preparation according to claim 1 or 2, characterized in that said heated or unheated cereal raw material comprises, in addition to rice germ and / or wheat germ and soybean, at least one of rice bran, hato-mugi (barley) or wheat. 4. Olieholdig præparation ifølge krav 1 eller 2, 30 kendetegnet ved, at den er indkapslet for oral indtagelse som en medicin eller helsekost.An oily preparation according to claim 1 or 2, 30, characterized in that it is encapsulated for oral ingestion as a medicine or health food. 5. Fremgangsmåde til at fremstille en olieholdig præparation ifølge krav 1, 2 eller 3, kendetegnet 35 ved, at det opvarmede kornråmateriale er opvarmet med lange infrarøde stråler, der har en bølgelængde af 4 til 14 DK 169714 B1 μπι.Process for preparing an oily preparation according to claim 1, 2 or 3, characterized in that the heated cereal raw material is heated by long infrared rays having a wavelength of 4 to 14 µ1 μπι. 6. Fremgangsmåde til at fremstille en olieholdig præparation ifølge krav 1, 2 eller 3, kendetegnet 5 ved, at kornråmaterialet er brygget ved 20 til 36°C i 2 til 6 dage efter behandling med varme.Process for preparing an oily preparation according to claim 1, 2 or 3, characterized in that the cereal raw material is brewed at 20 to 36 ° C for 2 to 6 days after heat treatment. 7. Fremgangsmåde til at fremstille en olieholdig præparation ifølge krav 1, 2 eller 3, kendetegnet 10 ved, at det fine pulver er tilsat til olieblandingen, således at den modnes ved 20 til 35°C i 3 til 30 dage.Process for preparing an oily preparation according to claim 1, 2 or 3, characterized in that the fine powder is added to the oil mixture so that it matures at 20 to 35 ° C for 3 to 30 days.
DK073293A 1992-06-22 1993-06-21 Oily Preparation and Method of Preparation DK169714B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4162666A JP2955126B2 (en) 1992-06-22 1992-06-22 Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof
JP16266692 1992-06-22

Publications (3)

Publication Number Publication Date
DK73293D0 DK73293D0 (en) 1993-06-21
DK73293A DK73293A (en) 1993-12-23
DK169714B1 true DK169714B1 (en) 1995-01-23

Family

ID=15758977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK073293A DK169714B1 (en) 1992-06-22 1993-06-21 Oily Preparation and Method of Preparation

Country Status (20)

Country Link
JP (1) JP2955126B2 (en)
KR (1) KR0138738B1 (en)
CN (1) CN1065433C (en)
AT (1) AT406935B (en)
AU (1) AU656681B2 (en)
BE (1) BE1006911A3 (en)
CA (1) CA2098893C (en)
CH (1) CH686482A5 (en)
DE (1) DE4320526C2 (en)
DK (1) DK169714B1 (en)
ES (1) ES2049189B1 (en)
FR (1) FR2692442B1 (en)
GB (1) GB2268185B (en)
HK (1) HK1007165A1 (en)
IS (1) IS1657B (en)
IT (1) IT1266950B1 (en)
NL (1) NL193398C (en)
NO (1) NO306932B1 (en)
SE (1) SE512781C2 (en)
TW (1) TW269630B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946548A (en) * 1956-09-10 1960-07-26 Lars G V Largelins Supporting clamp
GB9509811D0 (en) * 1995-05-15 1995-07-05 Cerestar Holding Bv Co-pressing of oilseeds
DE19715878A1 (en) * 1997-04-16 1998-10-22 Pharmaberatung Fuer Ernaehrung Products to aid the treatment of atopic dermatitis
JPH11269066A (en) * 1998-03-20 1999-10-05 Kao Corp Skin-bleaching agent for peroral administration and skin-bleaching food
AUPP574298A0 (en) * 1998-09-07 1998-10-01 Jacobs, David Ian Pharmaceutical preparation
JP2000159682A (en) * 1998-09-17 2000-06-13 Kozo Niwa Method of strengthening antitumor activity of crude drug, composition containing crude drug for strengthening antitumor activity, method of evaluating antitumor effectivity treated by crude drug and method of evaluating antitumor effectivity of crud drug
JP2000239187A (en) 1999-02-22 2000-09-05 Dotto:Kk Transnasal absorption composition
JP2001199892A (en) * 2000-01-17 2001-07-24 Kozo Niwa Method for enhancing antitumor activity of amygdalin- containing material, composition containing amygdalin- containing material for enhancing antitumor activity, method for evaluating antitumor effectiveness of treatment by amygdalin-containing material, and method for evaluating antitumor effectiveness of amygdalin- contaning material
JP4621444B2 (en) * 2004-06-18 2011-01-26 株式会社ヴァリダックス Method for producing antitumor substance
DE102007011985B4 (en) 2007-03-09 2022-10-20 Markus Greim Mortar measuring cell for rotation viscometer
FR2956324A1 (en) * 2010-01-18 2011-08-19 Valerie Baille Plant complex, useful to e.g. prepare a composition in pharmaceutical, cosmetic or nutrition, comprises a bamboo polyphenolic extract, a cell preparation of Ginkgo biloba and a rice bran oil preparation
CN104178334A (en) * 2013-05-24 2014-12-03 北京中天金谷粮油工程技术有限公司 Process for infrared baking of sesame to produce oil
JP2021031440A (en) * 2019-08-26 2021-03-01 雄二 松川 Antitumor agent set having active oxygen removing agent containing low molecular antioxidizing compound derived from natural product and immunity activator derived from natural product which is used for enhancing macrophages and lymphocytes
JP2021031439A (en) * 2019-08-26 2021-03-01 雄二 松川 Method for producing active oxygen scavenger for oral ingestion that suppresses runaway of immune cells and protects against dna and telomere damage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6020389B2 (en) * 1983-06-07 1985-05-21 工業技術院長 Separation method of tocopherols
JPS60110269A (en) * 1983-11-18 1985-06-15 Kimimoto Wada Preparation of vegetable nutrient
JPS6236327A (en) * 1985-08-08 1987-02-17 Kozo Niwa Chinese herbal remedy
JPS6379834A (en) * 1986-09-25 1988-04-09 Kozo Niwa Active oxygen suppressive composition
JPH023495A (en) * 1988-06-13 1990-01-09 Okuno Seiyaku Kogyo Kk Antioxidant
JPH0441436A (en) * 1990-06-04 1992-02-12 Sodetsukusu Kk Antioxidant composition
JPH07119176B2 (en) * 1990-09-28 1995-12-20 アサヒビール株式会社 Anti-active oxygen acting composition and anti-active oxygen agent containing the same as an active ingredient, food, cosmetics and pharmaceuticals
JP3357383B2 (en) * 1991-08-14 2002-12-16 昌宏 黒田 Low molecular weight plant composition
JP2647774B2 (en) * 1991-11-28 1997-08-27 株式会社 エイオーエイ・ジャパン Plant antioxidant composition

Also Published As

Publication number Publication date
FR2692442B1 (en) 1995-09-29
CA2098893A1 (en) 1993-12-23
SE512781C2 (en) 2000-05-15
AT406935B (en) 2000-10-25
DK73293D0 (en) 1993-06-21
KR0138738B1 (en) 1998-05-15
HK1007165A1 (en) 1999-04-01
ITTO930448A1 (en) 1994-12-21
IS4038A (en) 1993-12-23
JPH069421A (en) 1994-01-18
NO932282L (en) 1993-12-23
DK73293A (en) 1993-12-23
NL193398B (en) 1999-05-03
CH686482A5 (en) 1996-04-15
GB2268185B (en) 1996-01-24
AU656681B2 (en) 1995-02-09
TW269630B (en) 1996-02-01
AU4143293A (en) 1993-12-23
CA2098893C (en) 2000-05-16
NO306932B1 (en) 2000-01-17
IT1266950B1 (en) 1997-01-24
BE1006911A3 (en) 1995-01-24
ES2049189A1 (en) 1994-04-01
NO932282D0 (en) 1993-06-21
KR940000113A (en) 1994-01-03
JP2955126B2 (en) 1999-10-04
GB2268185A (en) 1994-01-05
GB9312763D0 (en) 1993-08-04
IS1657B (en) 1997-06-20
CN1087531A (en) 1994-06-08
ES2049189B1 (en) 1994-10-16
CN1065433C (en) 2001-05-09
ATA122893A (en) 2000-03-15
NL9301083A (en) 1994-01-17
NL193398C (en) 1999-09-06
FR2692442A1 (en) 1993-12-24
SE9302141D0 (en) 1993-06-21
DE4320526A1 (en) 1993-12-23
DE4320526C2 (en) 1996-09-19
SE9302141L (en) 1993-12-23
ITTO930448A0 (en) 1993-06-21

Similar Documents

Publication Publication Date Title
NL192914C (en) Method for the preparation of an antioxidant preparation and preparation obtained therewith.
DK169714B1 (en) Oily Preparation and Method of Preparation
US7887847B2 (en) Nutritional supplement for treatment of ocular diseases
US20110038985A1 (en) Black soybean hull extract, method for obtaining, and use thereof
RU2283124C1 (en) Biologically active preparation based on marine vegetable raw
KR20170086198A (en) Manufacturing method of diet solid tea including fermentation herb remedy and dietary fiber and the solid tea produced thereby
KR20140113050A (en) A composition containing onion skin hot water extracts as a active ingredient for the treatment of diabetes mellitus and blood vessel disease
KR100416650B1 (en) Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities
EP2452577B1 (en) Aqueous solution of phytin and use of said solution for preparing a liquid food supplement or a cosmetic composition
CN108719540A (en) A kind of decaffeination zinc-rich selenium instant tea and preparation method thereof
WO2005056031A1 (en) Lipase inhibitor
KR20120016962A (en) Composition comprising hizikia fusiformis for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases
JP3900967B2 (en) Antioxidants, skin cosmetics and beauty foods and drinks
JP2017014187A (en) Green juice for inhibiting increase of blood glucose level, green juice for antioxidation, green juice for controlling intestinal function, green juice for promoting collagen absorption, green juice for promoting calcium absorption, and green juice for inhibiting increase of blood cholesterol level
EP1161253A1 (en) Use of hop flowers for medicinal treatments
KR101095894B1 (en) A diabetes pharmaceutical composition and manufacturing process thereof
JP4368449B2 (en) Cataract prevention / treatment agent
CN109567199A (en) A kind of health food compound combination and its preparation method and application with norcholesterol
KR20150081701A (en) Antioxidative composition comprising extract of red tea stem
MXPA01008808A (en) Process for obtaining a food supplement against cancer.

Legal Events

Date Code Title Description
A0 Application filed
B1 Patent granted (law 1993)
PUP Patent expired